|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK- rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ)显示文摘 | Mok T Spigel D Felip E | 2015 | J Clin Oncol2015，33，： | 1 |
| 2 | Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or pla- cebo in combination with erlotinib in advanced NSCLC 显示文摘 | Spigel D R Ervin T J Ramlau R | 2011 | J Clin Oncol2011，，： | 1 |
| 3 | Randomized,phase Ⅱ multicenter,double-blind,placebo-controlled study evaluating MetMAb,an antibody to Met receptor,in combination with erlotinib,in patients with advanced non-small-cell lung cancer (OAM4558g)显示文摘 | Spigel D R Ervin T J Ramlau R | | 0，，8： | 1 |
| 4 | Final efficacy results from OAM4558g,a randomized phase Ⅱ study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC显示文摘 | Spigel D R Ervin T J Ranlau R | | 0，，： | 1 |
| 5 | Final efficacy re- suits from OAM4558g, a randomized phase Ⅱ study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC 显示文摘 | SPIGEL D R ERVIN T J RAMLAU R | 2011 | J Clin Oncol2011，29，15： | 1 |
| 6 | Efficacy and safety of PF-00299804(PF299) , an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor ( TKI ), as first-line treatment ( tx ) of selected patients ( pts ) with advanced ( adv ) non-small cell lung cancer ( NSCLC ) 显示文摘 | Mok T Spigel DR Park K | 2010 | J Clin Oncol2010，28，15： | 1 |
| 7 | Treatment Rationale Study Design for the MetLung Trial: a randomized, double-blind phase 111 study of onartuzumab ( MetMab ) in combination with er/otinib versus erlotinib alone in patients who have received standard chemotherapy for stage ⅢB or IV met-positive non-small- cell lung cancer显示文摘 | Spigel DR Edelman MJ Mok T | 2012 | Clin Lung Cancer2012，13，： | 1 |
| 8 | Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC 显示文摘 | Spigel D R Ervin T J Ramlau R | 2011 | J Clin Oncol2011，，： | 1 |
| 9 | Treatment rationale study design for the MetLung trial: a randomized, double-blind phase m study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemo- therapy for stage I B or IV Met-positive non-small-cell lung cancer 显示文摘 | Spigel DR Edelman MJ Mok T | 2012 | Clin Lung Cancer2012，13，6： | 1 |
| 10 | Stfiate palmoplantar keratoderma: a clinical and ultrastructural study显示文摘 | Helm T Spigel GT McMahon J | 1998 | Cutis1998，61，1： | 1 |
| 11 | Final efficacy results from OAM4558g, a randomized phase 11 study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC显示文摘 | SPIGEL D ERWIN T RAMLAU R | 2011 | J Clin Oncol2011，29，15： | 1 |
| 12 | American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus显示文摘 | Spigel T Moxlev RT | 1999 | Arch Dermatol1999，135，9： | 1 |
| 13 | Phase Ⅱ study of irinotecan and carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small cell lung cancer显示文摘 | Lubiner E T Spigel D R Greco F A | 2010 | J Clin Oncol 28:15s2010，7049，： | 1 |
| 14 | Random- ized phase I] trial of Onartuzumab in combination with erlo- tinib in patients with advanced non-small-cell lung cancer 显示文摘 | SPIGEL D R ERVIN T J RAMLAU R A | 2013 | J Clin Oncol2013，31，32： | 1 |
| 15 | Randomized phase II Trial of onartuzumab in combination with erlotinib in patients with advanced Non-Small - Cell lung cancer显示文摘 | Spigel D R Ervin T J Ramlau R A | 2013 | J Clin Oncol2013，31，32： | 1 |
| 16 | Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer显示文摘 | SPIGEL DR ERVIN T J RAMLAU RA | 2013 | J Clin Oncol2013，31，32： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员